Stock OBD OXFORD BIODYNAMICS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Oxford BioDynamics Plc

Equities

OBD

GB00BD5H8572

Delayed London S.E.
Other stock markets
 05:36:38 2024-04-29 am EDT 		5-day change 1st Jan Change
8.2 GBX +1.23% Intraday chart for Oxford BioDynamics Plc -6.82% -70.71%
Apr. 03 Oxford BioDynamics reaches "important milestone" with new laboratory AN
Apr. 03 Oxford BioDynamics Plc Opens Clinical Testing Facility in the UK to Perform EpiSwitch Prostate Screening Blood Test CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Oxford BioDynamics Plc - Bupa UK to cover EpiSwitch CiRT for customers with cancer
AQ
Bupa UK to cover EpiSwitch® CiRT for customers with cancer
BU
Oxford BioDynamics receives reimbursement code for EpiSwitch Prostate Screening Test
AQ
Oxford BioDynamics Receives Reimbursement Code for EpiSwitch® Prostate Screening (PSE) Test
BU
Oxford Biodynamics launches the 94% accurate EpiSwitch Prostate Screening blood test for men with prostate cancer risk in the US and UK
AQ
Oxford Biodynamics Announces US Launch of its 94% Accurate EpiSwitch® Prostate Screening Blood Test to Men With Prostate Cancer Risk
BU
Oxford Biodynamics' Prostate Screening EpiSwitch blood test significantly enhances overall detection accuracy for at risk men
AQ
Oxford BioDynamics’ Prostate Screening EpiSwitch® Blood Test Significantly Enhances Overall Detection Accuracy For At Risk Men
BU
Massachusetts General Hospital reports results of Interim Analysis from REFINE-ALS biomarker trial by Mitsubishi Tanabe Pharma USA, utilizing Oxford Biodynamics' EpiSwitch platform for prognostic stratification of fast progression ALS
AQ
Oxford BioDynamics in San Francisco for the 41st Annual J.P. Morgan Healthcare Conference
BU
Massachusetts General Hospital Reports Results of Interim Analysis from REFINE-ALS Biomarker Trial by Mitsubishi Tanabe Pharma USA, Utilizing Oxford Biodynamics’ EpiSwitch® Platform for Prognostic Stratification of Fast Progression ALS
BU
Prominent oncologist to discuss advantages of Oxford BioDynamics
AQ
Oxford BioDynamics’s Checkpoint Inhibitor Response Test (EpiSwitch® CiRT) Now Available in the UK
BU
Oxford BioDynamics Announces US Launch of Its Checkpoint Inhibitor Response Test (EpiSwitch® CiRT) for Oncology
BU
Oxford BioDynamics : Awarded US FNIH Grant to Apply EpiSwitch® Immune Health Test for Improved Prediction of Patient Response to Immune Checkpoint Inhibitor (ICI) Cancer Therapies
BU
Oxford BioDynamics : The Prime Meridian Group Collaborates With Oxford BioDynamics Plc On Market Research
PR
Oxford BioDynamics : Announces Strategic Partnership with Boca Biolistics in Order to Advance EpiSwitch™ Disease Severity Program for COVID-19
BU
Oxford BioDynamics : Advances EpiSwitch™ Disease Severity Program for COVID-19 with Top US Academic Health Center, Oregon Health & Science University
BU
Oxford BioDynamics : Board transition
PU
Oxford BioDynamics : Business update and notice of interim results
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OBD Stock
  4. News Oxford BioDynamics Plc
  5. Press Releases